ciprofibrate has been researched along with Diabetes Mellitus, Type 2 in 6 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofibrate has a potent hypolipidemic effect, especially a decrease in triglycerides, VLDL and fibrinogen, and an increase in HDL-cholesterol, but does not influence glycemic control nor insulin action." | 2.69 | Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects. ( Ascaso, JF; Carmena, R; Hernández-Mijares, A; Lluch, I; Martínez-Triguero, ML; Vizcarra, E, 2000) |
| "Dyslipidaemia in patients with type 2 diabetes commonly consists of elevated triglyceride levels; normal or slightly elevated low-density lipoprotein (LDL)-cholesterol levels with a preponderance of small, dense LDL particles; and low high-density lipoprotein (HDL)-cholesterol levels with a preponderance of small, dense HDL." | 2.42 | LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit? ( Taskinen, MR, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taskinen, MR | 1 |
| Okopień, B | 1 |
| Krysiak, R | 1 |
| Kowalski, J | 1 |
| Madej, A | 1 |
| Belowski, D | 1 |
| Zieliński, M | 1 |
| Herman, ZS | 1 |
| Evans, M | 1 |
| Anderson, RA | 1 |
| Graham, J | 1 |
| Ellis, GR | 1 |
| Morris, K | 1 |
| Davies, S | 1 |
| Jackson, SK | 1 |
| Lewis, MJ | 1 |
| Frenneaux, MP | 1 |
| Rees, A | 1 |
| Hernández-Mijares, A | 1 |
| Lluch, I | 1 |
| Vizcarra, E | 1 |
| Martínez-Triguero, ML | 1 |
| Ascaso, JF | 1 |
| Carmena, R | 1 |
| Raslová, K | 1 |
| Nagyová, A | 1 |
| Dobiásová, M | 1 |
| Ptácková, K | 1 |
| Dusinská, M | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
2 reviews available for ciprofibrate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Controlled Clinical Trials as | 2003 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
3 trials available for ciprofibrate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.
Topics: Adult; Anticholesteremic Agents; C-Reactive Protein; Clofibric Acid; Cytokines; Diabetes Mellitus, T | 2005 |
Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.
Topics: Adult; Analysis of Variance; Area Under Curve; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, | 2000 |
Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
Topics: Adult; Aged; Apolipoproteins B; Area Under Curve; Arteriosclerosis; Blood Glucose; Carbohydrate Meta | 2000 |
1 other study available for ciprofibrate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect of ciprofibrate on lipoprotien metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
Topics: Blood Glucose; Cholesterol; Clofibric Acid; Comet Assay; Diabetes Mellitus, Type 2; DNA Damage; Fibr | 2000 |